Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
1.670
+0.010 (0.60%)
Aug 4, 2025, 11:41 AM - Market open
Veren Employees
Aprea Therapeutics had 8 employees as of December 31, 2024. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
$160,559
Profits / Employee
-$1,760,160
Market Cap
9.24M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8 | 1 | 14.29% |
| Dec 31, 2023 | 7 | -2 | -22.22% |
| Dec 31, 2022 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
APRE News
- 5 weeks ago - Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center - GlobeNewsWire
- 2 months ago - Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update - GlobeNewsWire
- 4 months ago - Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial - GlobeNewsWire
- 4 months ago - Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 5 months ago - Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) - GlobeNewsWire
- 6 months ago - Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics - GlobeNewsWire
- 8 months ago - Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward - GlobeNewsWire
- 10 months ago - Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - GlobeNewsWire